Novo Nordisk A/S Dividend History (NVO)
🤑 Novo Nordisk A/S has distributed a total of 31 dividends from 2003 to 2024
📉 During this 21 period their dividend has seen a -1.14% decrease in the payout amount
About Novo Nordisk A/S
Novo Nordisk A/S is a renowned global healthcare company anchored in Denmark, primarily known for its leadership in diabetes care. Founded in 1923 through the merger of two Danish companies, Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium, the company has grown into one of the world’s largest producers of insulin. Novo Nordisk is dedicated to driving change in diabetes treatment with a wide spectrum of products ranging from insulin medications to systems for diabetes management. Besides diabetes care, the company is actively involved in research and development for other serious chronic conditions such as obesity, hemophilia, and growth disorders. With over 100 years in operation, Novo Nordisk is a key player in global health and innovation in the pharmaceutical industry. The company continues to thrive with significant revenues, reflecting its impact and presence in over 170 countries worldwide.
Apple Inc.
Microsoft Corporation
Johnson & Johnson
Procter & Gamble Co.
Coca-Cola Co.
PepsiCo, Inc.
Exxon Mobil Corporation
Verizon Communications Inc.
AT&T Inc.
Chevron Corporation
Amgen's weight loss drug candidate MariTide faces competition from Eli Lilly's Zepbound and Novo Nordisk's Wegovy. While MariTide has a convenience advantage with monthly dosing, its efficacy and tolerability are not significantly better than the incumbents. Amgen's stock is still worth buying on the dip as MariTide could potentially fill a niche for more tolerable and convenient weight loss solutions.
The Motley Fool · Published on Sat Nov 30 2024
Novo Nordisk, a Danish pharmaceutical company, has seen strong growth in recent years due to its GLP-1 drugs. While the company faces increasing competition, its pipeline of obesity and diabetes treatments, including the promising semaglutide, suggests continued growth potential. However, the stock's valuation and the competitive landscape warrant caution.
The Motley Fool · Published on Fri Nov 29 2024
Amgen's anti-obesity drug candidate MariTide experienced a loss of bone mineral density in a small number of patients during a phase 1 clinical trial. While the company says there is no major safety concern, the disclosure has caused a 6% drop in Amgen's stock price, and the company will need to reassure investors about the drug's potential.
The Motley Fool · Published on Fri Nov 29 2024Previous Payouts (31)
The most recent dividend Novo Nordisk A/S paid out was on August 26, 2024 (100 days ago) for $0.5169016 per share
| Pay Date | Amount |
|---|---|
| August 26, 2024 | $0.5169016 |
| April 2, 2024 | $0.9293348 |
| August 29, 2023 | $0.8763389 |
| April 4, 2023 | $1.1805812 |
| August 23, 2022 | $0.5777452 |
| April 5, 2022 | $1.022423 |
| August 25, 2021 | $0.5502889 |
| April 7, 2021 | $0.922122 |
| August 25, 2020 | $0.5177774 |
| April 7, 2020 | $0.7826048 |
| August 27, 2019 | $0.449438 |
| April 2, 2019 | $0.777006 |
| August 28, 2018 | $0.462327 |
| April 3, 2018 | $0.805982 |
| August 29, 2017 | $0.473821 |
| April 4, 2017 | $0.670368 |
| August 23, 2016 | $0.453459 |
| March 30, 2016 | $0.958141 |
| March 31, 2015 | $0.72998 |
| April 2, 2014 | $0.830304 |
| April 2, 2013 | $3.10179 |
| April 3, 2012 | $2.509455 |
| April 5, 2011 | $1.885974 |
| April 7, 2010 | $1.359188 |
| March 31, 2009 | $1.085462 |
| March 25, 2008 | $0.942309 |
| March 20, 2007 | $1.238582 |
| March 21, 2006 | $0.960768 |
| March 22, 2005 | $0.85729 |
| March 29, 2004 | $0.72356 |
| April 7, 2003 | $0.52287 |
Dividend data last updated Wed, 04 Dec 2024 23:32:52 GMT UTC